Armata Pharmaceuticals, Inc. (ARMP) - Dilution Analysis

10-Q filing | 0.0M shares outstanding

10-K filing | 36.2M shares outstanding

10-Q filing | 3.6M shares outstanding

10-Q filing | 36.2M shares outstanding

10-Q filing | 36.2M shares outstanding

10-K filing | 36.2M shares outstanding

10-Q filing | 36.2M shares outstanding

10-Q filing | 36.2M shares outstanding

10-Q filing | 36.1M shares outstanding

10-K filing | 36.1M shares outstanding

10-Q filing | 36.1M shares outstanding

10-Q filing | 36.1M shares outstanding

10-Q filing | 36.0M shares outstanding

S-3/A filing: Resale of common stock issuable upon conversion of a loan by selling shareholder.

10-K filing | 34.3M shares outstanding

S-3 filing: This S-3 filing registers 21,315,790 shares of common stock issuable upon conversion of a portion or all of the outstanding principal amount of, and any accrued and unpaid interest on, a loan.

10-Q filing | 36.0M shares outstanding

10-Q filing | 36.0M shares outstanding

S-3/A filing: This S-3/A filing relates to the disposition of up to 13,500,000 shares of common stock and 4,500,000 warrants to purchase common stock, initially issued pursuant to a Securities Purchase Agreement dated February 9, 2022.

S-3 filing: This is an S-3 filing for the resale of 9,000,000 shares of common stock, warrants to purchase 4,500,000 shares of common stock, and 4,500,000 shares of common stock issuable upon the exercise of the warrants.

10-Q filing | 36.1M shares outstanding

8-K filing: Armata Pharmaceuticals completed the second closing of a private placement with Innoviva Strategic Opportunities LLC, issuing shares of common stock and warrants. ($12.2M proceeds)

S-3 filing: This S-3 filing relates to the resale of up to 2,121,213 shares of common stock initially issued pursuant to a Securities Purchase Agreement dated October 28, 2021, along with information about private placements from 2020-2022.

10-K filing | 27.1M shares outstanding

8-K filing: Armata Pharmaceuticals, Inc. completed the first tranche of a private placement with Innoviva Strategic Opportunities LLC, selling 3,614,792 shares of common stock and warrants to purchase 1,807,396 shares for approximately $18.1 million. ($18.1M proceeds)

10-Q filing | 25.0M shares outstanding

8-K filing: Armata Pharmaceuticals, Inc. completed a private placement of newly issued shares of its common stock with Innoviva Strategic Opportunities LLC and the Cystic Fibrosis Foundation. ($14.0M proceeds)

10-Q filing | 24.9M shares outstanding

10-Q filing | 24.9M shares outstanding

S-3 filing: This prospectus relates to the disposition from time to time of up to (i) 6,153,847 shares of our common stock, $0.01 par value per share, (ii) warrants to purchase 6,153,847 shares of our common stock (the "_Warrants_"), and (iii) 6,153,847 shares of our common stock issuable upon the exercise of the Warrants, that were initially issued pursuant to the Securities Purchase Agreement dated as of January 26, 2021.

10-K filing | 24.9M shares outstanding

8-K filing: Armata Pharmaceuticals, Inc. completed the second closing of a private placement with Innoviva Strategic Opportunities LLC, involving the issuance of shares of common stock and warrants. ($6.1M proceeds)

8-K filing: Armata Pharmaceuticals, Inc. completed the first tranche of a private placement with Innoviva Strategic Opportunities LLC, selling 1,867,912 shares of common stock and warrants to purchase an equal number of shares at $3.25 per share, for gross proceeds of approximately $6.1 million. ($6.1M proceeds)

10-Q filing | 18.7M shares outstanding

10-Q filing | 18.7M shares outstanding

10-Q filing | 18.6M shares outstanding

S-3 filing: The filing registers an indeterminate amount of various securities, including common stock, that may be offered from time to time, with an aggregate offering price not to exceed $100,000,000.

S-3 filing: This prospectus relates to the disposition from time to time of up to (i) 8,710,800 shares of our common stock, $0.001 par value per share, and (ii) 8,710,800 shares of our common stock issuable upon exercise of the warrants for purchase of common stock

8-K filing: Armata Pharmaceuticals completed the second closing of a private placement with Innoviva, issuing shares of common stock and warrants. ($5.6M proceeds)

10-K filing | 10.9M shares outstanding

8-K filing: Armata Pharmaceuticals, Inc. completed the first closing of a private placement with Innoviva, Inc., issuing 993,139 shares of common stock and warrants for $2.8 million. ($5.6M proceeds)

RW filing: The company has decided to discontinue the public offering contemplated by the Registration Statement and requests immediate withdrawal due to an alternative financing opportunity.

8-K filing: Armata Pharmaceuticals, Inc. entered into a securities purchase agreement with Innoviva, Inc. to issue and sell up to 8,710,800 shares of common stock and warrants in a private placement priced at-the-market for gross proceeds of approximately $25.0 million. ($25.0M proceeds)

S-1/A filing: This S-1/A filing from Armata Pharmaceuticals, Inc. relates to an offering of 5,400,000 shares of common stock, with an underwriter option to purchase up to an additional 810,000 shares.